Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

☰

FDA to Publicly Disclose Advisory Committee Members' CVs

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-fda.jpg" NAME"FDA to Publicly Disclose Advisory Committee Members' CVs" ALT"FDA to Publicly Disclose Advisory Committee Members' CVs"February 8, 2017By Mark Terry, BioSpace.com Breaking News StaffThe <A HREF... Source: BioSpace

Continue ReadingFDA to Publicly Disclose Advisory Committee Members' CVs

Heads Up, Startups: Bayer AG is Bringing Its Grants4Apps Accelerator Program to San Francisco

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-bayer.jpg" NAME"Heads Up, Startups: Bayer AG is Bringing Its Grants4Apps Accelerator Program to San Francisco" ALT"Heads Up, Startups: Bayer AG is Bringing Its Grants4Apps Accelerator Program to San Francisco"February…

Continue ReadingHeads Up, Startups: Bayer AG is Bringing Its Grants4Apps Accelerator Program to San Francisco

Merck KGaA Spinout Prexton Nabs $31 Million to Fund Phase II Parkinson's Trials

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-Merck-KGaA-Germany.jpg" NAME"Merck KGaA Spinout Prexton Nabs $31 Million to Fund Phase II Parkinson's Trials" ALT"Merck KGaA Spinout Prexton Nabs $31 Million to Fund Phase II Parkinson's Trials"February 7, 2017By…

Continue ReadingMerck KGaA Spinout Prexton Nabs $31 Million to Fund Phase II Parkinson's Trials

Genentech's $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-genentech.jpg" NAME"Genentech's $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire" ALT"Genentech's $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire"February 7, 2017By Mark Terry, BioSpace... Source: BioSpace

Continue ReadingGenentech's $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire